NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Genmab A/S (CO: GMAB)

 
GMAB Technical Analysis
5
As on 25th Mar 2025 GMAB STOCK Price closed @ 1322.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1993.45 & Strong Sell for SHORT-TERM with Stoploss of 2151.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GMABSTOCK Price

Open 1343.00 Change Price %
High 1358.50 1 Day -3.00 -0.23
Low 1320.50 1 Week -92.00 -6.51
Close 1322.00 1 Month -50.50 -3.68
Volume 107941 1 Year -1188.00 -47.33
52 Week High 2510.00 | 52 Week Low 1363.50
 
CO Denmark Most Active Stocks
SAS 0.01 0.00%
NOVO-B 512.40 -1.78%
ALMB 16.72 1.21%
VWS 104.85 0.82%
DANSKE 238.80 3.11%
CONFRZ 0.01 0.00%
GREENH 0.39 8.33%
ASTRLS 1.15 8.49%
BLVIS-A 0.40 -18.37%
AMBU-B 125.00 1.09%
 
CO Denmark Top Gainers Stocks
HYDRCT 0.60 46.34%
HYPE 3.66 22.00%
DAC 9.00 20.00%
DAC 9.00 20.00%
DAC 9.00 20.00%
DKIEEU 249.00 15.81%
ALEFRM 2.10 13.51%
SAME 1.45 10.69%
SAME 1.45 10.69%
ASTRLS 1.15 8.49%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
BLVIS-A 0.40 -18.37%
MAPS 0.88 -10.20%
MAPS 0.88 -10.20%
MAPS 0.88 -10.20%
MAPS 0.88 -10.20%
NEWCAP 0.09 -10.00%
HAPPY 0.18 -10.00%
SCAPE 0.11 -8.33%
WIRTEK 6.55 -6.43%
 
 
GMAB
Daily Charts
GMAB
Intraday Charts
Whats New @
Bazaartrend
GMAB
Free Analysis
 
GMAB Important Levels Intraday
RESISTANCE1395.23
RESISTANCE1371.74
RESISTANCE1357.23
RESISTANCE1342.71
SUPPORT1301.29
SUPPORT1286.77
SUPPORT1272.26
SUPPORT1248.77
 
GMAB Forecast March 2025
4th UP Forecast1769.06
3rd UP Forecast1625.69
2nd UP Forecast1537.06
1st UP Forecast1448.44
1st DOWN Forecast1195.56
2nd DOWN Forecast1106.94
3rd DOWN Forecast1018.31
4th DOWN Forecast874.94
 
GMAB Weekly Forecast
4th UP Forecast2250.81
3rd UP Forecast1952.94
2nd UP Forecast1768.81
1st UP Forecast1584.69
1st DOWN Forecast1059.31
2nd DOWN Forecast875.19
3rd DOWN Forecast691.06
4th DOWN Forecast393.19
 
GMAB Forecast2025
4th UP Forecast3696.06
3rd UP Forecast2934.69
2nd UP Forecast2464.06
1st UP Forecast1993.44
1st DOWN Forecast650.56
2nd DOWN Forecast179.94
3rd DOWN Forecast-290.69
4th DOWN Forecast-1052.06
 
 
GMAB Other Details
Segment EQ
Market Capital 191580389376.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
GMAB Address
GMAB
 
GMAB Latest News
 
Your Comments and Response on Genmab A/S
 
GMAB Business Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Address: Kalvebod Brygge 43, Copenhagen, Denmark, 1560
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service